Published in Science · View the paper (DOI)
Neoleukin Therapeutics announces a novel protein decoy NL-CVX1 that blocks SARS-CoV-2 infection in vitro. The lead molecule is shown to protect hamsters from lethal doses of the virus through intranasal administration. This development demonstrates the potential of de novo protein design technology for addressing biological problems.
Coverage from 2 institutions